Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

No Seed Oil-Colon Cancer Link; Avoiding Prostate Biopsy; Top Cancer Advances

2.

GLP-1 Receptor antagonists used in a study allay fears about thyroid cancer.

3.

Immune cell homing hydrogel-based platform captures dendritic cells to process mRNA from cancer vaccines

4.

Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.

5.

The September 2018 issue of Medical Bulletin.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot